Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Equity Average (2016 - 2026)

Ironwood Pharmaceuticals' Equity Average history spans 15 years, with the latest figure at -$263.0 million for Q4 2025.

  • On a quarterly basis, Equity Average rose 14.15% to -$263.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$263.0 million, a 14.15% increase, with the full-year FY2025 number at -$281.6 million, down 153.44% from a year prior.
  • Equity Average hit -$263.0 million in Q4 2025 for Ironwood Pharmaceuticals, up from -$286.2 million in the prior quarter.
  • Over the last five years, Equity Average for IRWD hit a ceiling of $679.6 million in Q1 2023 and a floor of -$336.2 million in Q3 2023.
  • Historically, Equity Average has averaged $161.0 million across 5 years, with a median of $245.5 million in 2021.
  • Biggest five-year swings in Equity Average: skyrocketed 3627.52% in 2021 and later crashed 281.14% in 2024.
  • Tracing IRWD's Equity Average over 5 years: stood at $592.9 million in 2021, then rose by 4.86% to $621.7 million in 2022, then decreased by 17.2% to $514.8 million in 2023, then plummeted by 159.51% to -$306.3 million in 2024, then rose by 14.15% to -$263.0 million in 2025.
  • Business Quant data shows Equity Average for IRWD at -$263.0 million in Q4 2025, -$286.2 million in Q3 2025, and -$321.1 million in Q2 2025.